Allogeneic Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: Results from the MANTLE-FIRST Study on Behalf of Fondazione Italiana Linfomi

Investigators retrospectively analyzed 55 patients who underwent llogeneic stem cell transplantation for mantle cell lymphoma relapsed or refractory after rituximab and high-dose cytarabine within the MANTLE-FIRST project.
[Leukemia & Lymphoma]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Investigators reported on all 17 patients with BPDCN who underwent allogeneic hematopoietic cell transplantation (allo-HCT) at their center between 2000 and 2020, and concluded that allo-HCT provided long-lasting remissions in BPDCN patients, particularly when performed in complete remission.
[Bone Marrow Transplantation]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Posttransplant Blockade of CXCR4 Improves Leukemia Complete Remission Rates and Donor Stem Cell Engraftment without Aggravating GVHD

The authors found that posttransplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the bone marrow in patient-derived xenograft mice grafted with B cell acute lymphoblastic leukemia cells from multiple patients.
[Cellular & Molecular Immunology]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Emerging Approaches to Improve Allogeneic Hematopoietic Cell Transplantation Outcomes for Non-malignant Diseases

Scientists discuss the current approach to each of these clinical issues and how emerging novel therapeutics hold promise to advance transplant care for patients with non-malignant diseases.
[Blood]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

ATG and Post-Transplant Cyclophosphamide Predisposes to Inferior Outcome When Using Cryopreserved Stem Cell Grafts

Scientists analyzed the outcomes of 483 patients who received HSCT between August 2017 and August 2020 in aretrospective study, comparing the outcomes between those who received cryopreserved or fresh peripheral blood stem cell grafts.
[European Journal of Haematology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Outcomes and Toxicity of Allogeneic Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second-Generation Tyrosine Kinase Inhibitors: A Prospective Non-Interventional Study from the Chronic Malignancy Working Party of the EBMT

Scientists presented the results of a prospective non-interventional study performed by the EBMT on 383 consecutive chronic myeloid leukemia patients previously treated with dasatinib or nilotinib undergoing allogeneic hematopoietic cell transplantation from 2009 to 2013.
[Bone Marrow Transplantation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

The Importance of Endothelial Protection: The Emerging Role of Defibrotide in Reversing Endothelial Injury and Its Sequelae

Further preclinical and clinical studies will explore defibrotide’s potential utility in a broader range of disorders resulting from endothelial cell activation and dysfunction.
[Bone Marrow Transplantation]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Venetoclax plus Azacitidine and Donor Lymphocyte Infusion in Treating Acute Myeloid Leukemia Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Scientists evaluated the efficacy and safety of venetoclax plus azacitidine and donor lymphocyte infusion in treating patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
[Annals of Hematology]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Peritransplant Ruxolitinib Administration Is Safe and Effective in Patients with Myelofibrosis: A Pilot Open-Label Study

Investigators reported results of a prospective pilot trial evaluating the safety/feasibility of peri-transplant administration of ruxolitinib for myelofibrosis treatment. Peri-HCT ruxolitinib was safe and well-tolerated with the maximum tolerated dose determined as 10 mg BID, associated with dose-dependent PK and cytokine profile.
[Blood Advances]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Haploidentical vs. Sibling, Unrelated, or Cord Blood Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Scientists compared overall survival between haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamid and HLA-matched sibling donor, 8/8 HLA-matched unrelated donor, 7/8 HLA-matched UD, or umbilical cord blood HCT.
[Blood Advances]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Altered Effect of Killer Immunoglobulin-Like Receptor–Ligand Mismatch by Graft versus Host Disease Prophylaxis in Cord Blood Transplantation

The difference in the effect of killer immunoglobulin-like receptor–ligand mismatch was retrospectively assessed between patients who received cord blood transplantation for acute leukemia, myelodysplastic syndrome, or chronic myeloid leukemia, as well as GVHD prophylaxis comprising tacrolimus plus methotrexate or mycophenolate mofetil.
[Bone Marrow Transplantation]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share